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There is a natural tendency to simplify the findings of a clini-cal trial into a binary conclusion: “Was there a positive outcome — or not?” In order to address this question with some objectivity, attention is typi-
cally focused on whether the prespecified measure of success for the primary 
outcome has been met — that is, whether a P value of less than 0.05 has been 
achieved for the difference in treatments. In reality, a more nuanced interpretation 
requires a thorough examination of the totality of the evidence, including second-
ary end points, safety issues, and the size and quality of the trial. In this article, 
which focuses on the evaluation of “positive” studies — as in our previous article,1 
which focused on the appraisal of “negative” studies — our intent is to facilitate 
a more sophisticated and balanced interpretation of trial evidence. Again, we make 
our points using examples from trials involving cardiovascular disease (our area 
of expertise), but the messages can be easily applied to other subject areas.
K e y Ques tions W hen the Pr im a r y Ou t come Is  Posi ti v e
The achievement of statistical significance for the primary outcome is typically a 
necessary prerequisite for the adoption of a new therapy, but it is not sufficient. 
The totality of trial results will be scrutinized by numerous stakeholders, including 
regulators, payers, journal editors and reviewers, clinical experts, guidelines com-
mittees, physicians, patients, and critics. The determination of whether the find-
ings provide evidence that is sufficient to modify medical practice requires in-depth 
interpretation of the trial data and the results of earlier, related trials. Answering 
the key questions discussed below (and listed in Table 1) may help to identify 
which “positive” trials provide evidence that is sufficient to advance clinical practice. 
In this regard, we also acknowledge that studies that unexpectedly reveal harm 
(e.g., the CAST trial [see box for a list of the complete names of all trials men-
tioned in this article], which revealed that antiarrhythmic therapy was associated 
with an increase in mortality2) may equally inform medical practice, although 
here, too, close scrutiny of the validity of the results is warranted.
Is a P Value of Less Than 0.05 Good Enough?
A P value of 0.05 carries a 5% risk of a false positive result (i.e., there is no true 
difference between treatments). If a trial is meant to provide proof of a genuine 
treatment difference beyond reasonable doubt, a much smaller P value — say, 
P<0.001 — is required.3 For instance, the PARADIGM-HF trial4 of sacubitril– 
valsartan versus enalapril in patients with heart failure showed overwhelming ben-
efit (P<0.00001) with respect to the composite primary outcome of cardiovascular 
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death or hospitalization for heart failure, which 
justified regulatory approval and the clinical 
adoption of sacubitril–valsartan. In contrast, in 
the SAINT I trial5 of NXY-059, a free-radical–
trapping agent, versus placebo for the treatment 
of acute ischemic stroke, the P value for the 
primary outcome of disability at 90 days was 
0.038 — not strong evidence of efficacy. A sec-
ond, larger trial (SAINT II6) was needed and re-
vealed no significant effect (P = 0.33), which 
prompted the authors to conclude that “NXY-059 
is ineffective for the treatment of acute ischemic 
stroke.”
What Is the Magnitude of Treatment Benefit?
Beyond statistical significance, a treatment dif-
ference needs to be clinically meaningful — that 
is, large enough to matter. This determination 
requires examination of the treatment effect on 
both a relative scale (e.g., by calculation of the 
relative risk or the hazard ratio) and an absolute 
scale (e.g., by calculation of the differences in 
the rates of events during follow-up and in the 
number needed to treat). In addition, the extent 
of uncertainty in the estimated effect should be 
considered by examining the 95% confidence 
interval. For instance, if the P value is close to 
0.05, the confidence interval will range from 
almost no effect to an upper boundary that is 
considerably larger than the point estimate.
An illustration of these concepts is provided 
in the IMPROVE-IT trial,7 in which ezetimibe was 
compared with placebo in patients with acute 
coronary syndromes who were being treated 
with simvastatin; the hazard ratio for the com-
posite primary outcome of cardiovascular death, 
myocardial infarction, unstable angina, revascu-
larization, or stroke was 0.94 (95% confidence 
interval [CI], 0.89 to 0.98; P = 0.016). The 7-year 
primary event rates were 32.7% with ezetimibe 
versus 34.7% with placebo (Fig. 1), a difference 
of 2 percentage points, with a 95% confidence 
interval that ranged from close to 0 to 4 percent-
age points. Although the findings for this trial 
were described as “positive,” one might question 
whether the benefit of ezetimibe is large enough 
to warrant its cost and potential complications. 
An advisory panel from the Food and Drug Ad-
ministration (FDA) recommended against expand-
ing the ezetimibe label to include an indication 
for a reduction in cardiovascular events.8
Is the Primary Outcome Clinically Important 
(and Internally Consistent)?
Surrogate Outcomes
Although phase 3 trials are usually powered to 
achieve clinically relevant outcomes, for some 
diseases a surrogate primary outcome measure 
has been accepted (e.g., a reduction in glycated 
hemoglobin levels as an indication of antiglyce-
Does a P value of <0.05 provide strong enough evidence?
What is the magnitude of the treatment benefit?
Is the primary outcome clinically important (and internally consistent)?
Are secondary outcomes supportive?
Are the principal findings consistent across important subgroups?
Is the trial large enough to be convincing?
Was the trial stopped early?
Do concerns about safety counterbalance positive efficacy?
Is the efficacy–safety balance patient-specific?
Are there flaws in trial design and conduct?
Do the findings apply to my patients?
Table 1. Key Questions to Ask When the Primary Outcome Is Positive.
ACCORD: Action to Control Cardiovascular Risk in Diabetes.
ATLAS ACS 2–TIMI 51: Anti-Xa Therapy to Lower Cardiovascular Events in 
Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–
Thrombolysis in Myocardial Infarction 51.
CAST: Cardiac Arrhythmia Suppression Trial.
COMPLETE: Complete vs. Culprit-Only Revascularization to Treat Multi-vessel 
Disease after Primary PCI for STEMI.
DAPT: Dual Antiplatelet Therapy.
EMPA-REG OUTCOME: Empagliflozin Cardiovascular Outcome Event Trial in 
Type 2 Diabetes Mellitus Patients.
EXPEDITION: Na+/H+ Exchange Inhibition to Prevent Coronary Events in 
Acute Cardiac Condition.
FAME 2: Fractional Flow Reserve versus Angiography for Multivessel 
Evaluation.
FREEDOM: Future Revascularization Evaluation in Patients with Diabetes 
Mellitus: Optimal Management of Multivessel Disease.
IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International 
Trial.
LIDO: Levosimendan Infusion versus Dobutamine.
PARADIGM-HF: Prospective Comparison of ARNI (Angiotensin Receptor–
Neprilysin Inhibitor) with ACEI (Angiotensin-Converting–Enzyme Inhibitor) 
to Determine Impact on Global Mortality and Morbidity in Heart Failure 
Trial.
PLATO: Study of Platelet Inhibition and Patient Outcomes.
PRAMI: Preventive Angioplasty in Acute Myocardial Infarction.
RITA-3: Randomized Intervention Trial of Unstable Angina.
SAINT I and II: Stroke–Acute Ischemic NXY Treatment.
SPRINT: Systolic Blood Pressure Intervention Trial.
SURVIVE: Survival of Patients with Acute Heart Failure in Need of Intravenous 
Inotropic Support.
SYMPLICITY HTN-2 and -3: Renal Denervation in Patients with Uncontrolled 
Hypertension.
SYNTAX: Synergy between Percutaneous Coronary Intervention with Taxus 
and Cardiac Surgery.
TAPAS: Thrombus Aspiration during Percutaneous Coronary Intervention in 
Acute Myocardial Infarction Study.
Trial Names.
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mic efficacy in patients with diabetes). However, 
the findings of some large-scale trials have 
raised questions about the wisdom of such reli-
ance on surrogate markers.9 For instance, in the 
ACCORD trial,10 intensive therapy resulted in 
markedly lower glycated hemoglobin levels than 
standard therapy, but the rate of cardiovascular 
events was not significantly lower, and mortality 
was higher. Similarly, in the LIDO trial, levosi-
mendan resulted in greater hemodynamic im-
provement (the primary outcome) than dobuta-
mine in patients with acute heart failure,11 which 
resulted in the regulatory approval of levosimen-
dan in many countries. However, SURVIVE, the 
larger, subsequent trial of levosimendan versus 
dobutamine,12 showed no evidence of a treatment 
benefit for the primary outcome — 180-day 
mortality (P = 0.40) — and levosimendan was not 
approved by the FDA.
Composite Outcomes
Positive composite primary outcomes must be 
carefully inspected to determine which compo-
nents are driving the result. For instance, in the 
RITA-3 trial,13 which assessed the effects of in-
terventional versus conservative management in 
patients with acute coronary syndromes, fewer 
patients in the intervention group had a compos-
ite primary outcome event of death, myocardial 
infarction, or refractory angina at 4 months 
(9.6% vs. 14.5%, P = 0.001). When the trial find-
ings were presented at a European Society of 
Cardiology Congress, a newsletter headline read 
“RITA-3: First Proof Intervention Saves Lives” 
— an incorrect interpretation, since this finding 
was driven by a halving of the rate of refractory 
angina, with no evidence of a difference in the 
rates of death or myocardial infarction in the 
short term. At the time, the question of whether 
the data justified the use of a routine invasive 
strategy was debatable, given its up-front risks 
and costs. Fortunately, a 5-year follow-up study14 
revealed a 22% lower rate of death or myocar-
dial infarction in the intervention group than in 
the conservative management group (P = 0.04), 
and subsequent meta-analyses15,16 have support-
ed the use of an early interventional approach in 
patients with acute coronary syndromes to im-
prove prognosis.
More strikingly, the EXPEDITION trial17 of cari-
poride versus placebo in high-risk patients under-
going coronary-artery bypass grafting (CABG) 
had a very positive result (P = 0.0002) for the 
primary composite outcome of death or myo-
cardial infarction. However, this outcome was 
driven by a reduction in myocardial infarction 
(P = 0.000005), whereas mortality was higher 
with cariporide (P = 0.02), as was the rate of cere-
brovascular events (P<0.001). These findings led 
to the abandonment of cariporide for this indi-
cation.
Are Secondary Outcomes Supportive?
Confidence in the overall “positivity” of a trial is 
enhanced if prespecified secondary outcomes also 
show a treatment benefit. Conversely, if second-
ary outcomes show no hint of benefit, doubts 
will materialize. For instance, in the SAINT I 
trial5 of NXY-059 in acute ischemic stroke, no evi-
dence of benefit existed for two key secondary 
outcomes — scores on the National Institutes of 
Health Stroke Scale and the Barthel Index. This 
absence of evidence enhanced suspicion regard-
ing the “positive” primary outcome, a suspicion 
that was reinforced by the negative result in the 
sequel trial, SAINT II.6
In contrast, in the EMPA-REG OUTCOME trial18 
Figure 1. Primary Outcome Results from IMPROVE-IT.
Shown is the rate of the primary composite outcome of cardiovascular 
death, myocardial infarction, unstable angina, revascularization, or stroke in 
IMPROVE-IT, among patients who received ezetimibe in addition to simva-
statin as compared with those who received placebo with simvastatin. Among 
18,144 patients with an acute coronary syndrome, the rate of the primary 
outcome over 7 years of follow-up was 32.7% with ezetimibe plus simva-
statin, as compared with 34.7% with placebo plus simvastatin, for an ab-
solute difference of 2.0 percentage points. The inset shows the same data 
on an enlarged y axis. Adapted from Cannon et al.7
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of empagliflozin versus placebo in type 2 diabe-
tes, the benefit of empagliflozin with respect to 
the composite primary outcome (cardiovascular 
death, myocardial infarction, or stroke) was of 
borderline significance, with a hazard ratio of 
0.86 (95% CI, 0.74 to 0.99; P = 0.04). However, 
this finding was driven by a robustly lower rate 
of cardiovascular death (hazard ratio, 0.62; 95% 
CI, 0.49 to 0.77; P<0.001) and was reinforced 
by similar findings regarding all-cause death 
(P<0.001) and hospitalizations for heart failure 
(P = 0.002). Thus, the effect of empaglif lozin 
was observed mainly in the secondary outcomes, 
although the positive finding for the primary 
outcome imparted initial credibility.
Are Findings Consistent across Important 
Subgroups?
Relative treatment effects may vary according to 
patient characteristics. Alternatively, a consistent 
relative treatment effect across all patient types 
may be observed, but certain high-risk sub-
groups may have greater absolute benefits, as 
has been seen with statins in patients with mul-
tiple cardiac risk factors.19 Long-term statin use 
in primary prevention is thus commonly con-
fined to patients with a sufficiently high base-
line risk.
More challenging is the situation in which 
subgroup analyses in a “positive” trial identify 
patients who do not appear to benefit from the 
new treatment. Caution is warranted, since spu-
rious findings can arise when multiple sub-
groups are analyzed.20 Nonetheless, protecting 
such patients from a treatment that appears to 
be ineffective (or harmful) may be warranted, 
depending on the strength of the statistical inter-
action and its biologic plausibility.
For instance, in the PLATO trial21,22 involving 
patients with an acute coronary syndrome, the 
risk of the composite primary outcome of cardio-
vascular death, myocardial infarction, or stroke 
was 16% lower with ticagrelor than with clopi-
dogrel in the overall study population (P<0.001). 
However, among patients receiving a high main-
tenance dose of aspirin, the risk was 45% higher 
with ticagrelor than with clopidogrel, whereas 
among patients receiving a low maintenance 
dose, ticagrelor was associated with a 21% lower 
risk (P = 0.0006 for the interaction) (Fig. 2). Al-
though the validity of this observation is still 
disputed (it arose from numerous exploratory 
subgroup analyses and lacks obvious biologic 
plausibility), the FDA issued a warning that a 
maintenance dose of more than 100 mg of aspirin 
reduces the effectiveness of ticagrelor and should 
be avoided.
Is the Trial Large Enough to Be Convincing?
When a small clinical trial achieves statistical 
significance for its primary outcome, cautious 
interpretation is warranted. Small trials lack 
power, so positive treatment effects are suscep-
tible to exaggeration, and false positives may 
occur.
For instance, in a trial of N-acetylcysteine ver-
sus placebo to prevent nephropathy induced by 
radiocontrast agents,23 1 of 41 patients receiving 
N-acetylcysteine had a primary outcome event, 
as compared with 9 of 42 patients who were re-
ceiving placebo, resulting in a relative risk with 
N-acetylcysteine of 0.10 (95% CI, 0.02 to 0.90; 
P = 0.01). On the basis of this small trial, the 
stated conclusion that N-acetylcysteine is “an ef-
fective means of preventing renal damage” is 
too strong; a more appropriate statement is that 
N-acetylcysteine “may be effective.” Such a con-
clusion would motivate the conduct of a larger, 
more definitive trial. Unfortunately, a subsequent 
meta-analysis24 of 10 randomized trials (1916 
patients) reported that the evidence was too weak 
and heterogeneous to support use of N-acetylcys-
teine for this indication.
Similarly, in the PRAMI trial, 465 patients 
with ST-segment elevation myocardial infarction 
(STEMI) and multivessel disease who were un-
Figure 2. Apparent Interaction between a Maintenance Dose of Aspirin  
and Randomization to Ticagrelor or Clopidogrel and the Primary Efficacy 
End Point from the PLATO Trial.
In the PLATO trial, which involved 18,624 patients who presented with an 
acute coronary syndrome, ticagrelor was more effective than clopidogrel 
with respect to the primary composite outcome of cardiovascular death, 
myocardial infarction, or stroke among patients who were on a low main-
tenance dose of aspirin (<300 mg) but not among those who were on a 
high maintenance dose of aspirin (≥300 mg), a qualitative interaction that 
was statistically significant. Data are from Carroll et al.22
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dergoing primary percutaneous coronary inter-
vention (PCI) were randomly assigned to receive 
preventive angioplasty (complete revasculariza-
tion during the index procedure) or initial angio-
plasty of the infarct artery only.25 The hazard 
ratio for the composite primary outcome (refrac-
tory angina, myocardial infarction, or cardiac 
death) with preventive angioplasty versus angio-
plasty of the infarct artery only was 0.35 (95% 
CI, 0.21 to 0.58; P<0.001), with similarly lower 
risks for each of the three components. This 
controversial finding was based on relatively few 
primary events (21 in the intervention group vs. 
53 in the group receiving standard care) and 
selective enrollment (recruitment took 5 years 
and was stopped early), giving the impression 
that the 65% reduction in hazard was too good to 
be true. Two subsequent, similarly sized trials26,27 
showed mixed results. Thus, more evidence is 
needed to justify such a radical change in STEMI 
management, and the results of the ongoing, 
large-scale COMPLETE trial28 are awaited with 
interest.
Was the Trial Stopped Early?
Sometimes a trial is stopped early because in-
terim results show strong evidence of treatment 
superiority, which is often a newsworthy event. 
Unfortunately, this practice tends to exaggerate 
treatment efficacy.29 As a trial progresses, the 
estimated treatment effect varies randomly in 
relation to the true effect. If the interim estimate 
is based on a randomly high indication of effi-
cacy, it is more likely to cross a statistical stop-
ping boundary and to convince a data and safety 
monitoring board that overwhelming evidence 
of benefit exists. Stopping early also truncates 
evidence for important secondary (and safety) 
outcomes.
In the FAME 2 trial,30 for example, PCI was 
compared with medical therapy alone in patients 
with stable coronary artery disease and hemody-
namically significant lesions (as assessed by 
means of fractional f low reserve). The trial was 
stopped early because the hazard ratio for the 
primary outcome (all-cause death, myocardial 
infarction, or urgent revascularization) favoring 
PCI was 0.39 (95% CI, 0.26 to 0.57; P<0.001). 
This benefit with PCI was driven by fewer urgent 
revascularizations, an arguably “soft” outcome 
in an unblinded trial. The rate of death or myo-
cardial infarction, although lower with PCI (haz-
ard ratio 0.79; 95% CI, 0.49 to 1.29; P = 0.35), 
was inconclusive. Had the trial continued to its 
intended completion, a significantly lower rate of 
death or myocardial infarction may have emerged, 
which would have greatly enhanced the value of 
the trial.
Another recent example is the SPRINT trial31 
of intensive versus standard blood-pressure con-
trol, which had a composite primary outcome of 
myocardial infarction, acute coronary syndrome, 
stroke, heart failure, or cardiovascular death. The 
trial was stopped early at a median of 3.26 years 
rather than at the intended 5-year follow-up, and 
at the time the trial was stopped, the hazard 
ratio for the primary outcome with intensive 
control was 0.75 (95% CI, 0.64 to 0.89; P<0.001). 
The exceptional speed to publication was sur-
prising32; only 4 weeks lapsed between the time 
that the trial was stopped and the time at which 
the manuscript was submitted for publication. 
The quality and completeness of any interim 
database are inevitably imperfect — there will 
be outstanding primary (and other) events yet to 
be ascertained and adjudicated. In addition, the 
moment at which a trial is stopped is the time 
at which an exaggerated estimate of efficacy is 
more likely to be present. Orderly trial closure 
after early stoppage takes several months and is 
necessary to achieve robust interpretation of all 
the evidence. Earlier reporting of preliminary, 
incomplete results is usually unwise.
Do Concerns about Safety Counterbalance 
Positive Efficacy?
When a new treatment has superior efficacy, it is 
important to identify concerns about safety that 
might offset the benefits. A balanced account of 
both efficacy and safety must be provided.33 Ab-
solute benefits and risks should be presented in 
terms of differences in percentages. Consider-
ation of the number needed to treat for benefit 
versus the number needed to harm may provide 
a guide to net clinical benefit.
In the DAPT trial,34 for example, an addi-
tional 18 months of dual antiplatelet therapy 
versus aspirin alone beginning 1 year after the 
implantation of a drug-eluting stent resulted in 
rates of major adverse cardiac and cerebrovascu-
lar events and of stent thromboses (the two 
primary efficacy outcomes) that were lower by 
1.6% and 1.0%, respectively. However, this ben-
efit came at the cost of higher rates of major 
bleeding events. According to Global Use of 
Strategies to Open Occluded Arteries (GUSTO) 
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criteria, the rate of “moderate or severe” bleed-
ing events was 0.9% higher with continued dual 
antiplatelet therapy, and according to Bleeding 
Academic Research Consortium (BARC) criteria, 
the rate of bleeding that required medical atten-
tion was 2.7% higher. All-cause mortality was 
0.5% higher with prolonged dual antiplatelet 
therapy (P = 0.05), and this change was attributed 
primarily to greater noncardiovascular mortality 
(P = 0.002), although some experts have argued 
that the higher rates of death may have been due 
to chance. Debate ensues: Is the net effect of 
prolonged dual antiplatelet therapy in this popu-
lation beneficial or harmful?
Similarly, in the SPRINT trial,31 intensive low-
ering of blood pressure resulted in a rate of the 
primary composite cardiovascular outcome that 
was 1.6 percentage points lower and a rate of 
death that was 1.2 percentage points lower than 
the rates with standard blood-pressure control 
during a median follow-up period of 3.26 years. 
However, these benefits must be weighed against 
rates of hypotension, syncope, and acute kidney 
injury, which were higher (by 1.4 percentage 
points, 1.1 percentage points, and 1.8 percent-
age points, respectively) with intensive blood-
pressure control (Fig. 3). Note that all these 
benefits and risks, although statistically signifi-
cant, represent small absolute differences. Thus, 
guideline committees, treating physicians, and 
patients face a challenge when trying to deter-
mine which strategy to adopt.
Is the Balance of Efficacy and Safety Patient-
Specific?
The net clinical benefit of a new treatment may 
be patient-specific — that is, worthwhile for 
those at an increased risk for the primary effi-
cacy outcome but deleterious for those at an in-
creased risk for adverse events. Calculating the 
individual patient trade-offs between efficacy 
and safety is not straightforward, and statistical 
modeling techniques may be useful.35
For the DAPT trial,34 multivariable models 
were developed for predicting the risk of myo-
cardial infarction or stent thrombosis and the 
risk of major bleeding.36 In addition to account-
ing for the duration of antiplatelet treatment 
(12 months vs. 30 months), these models in-
cluded 9 patient and procedural characteristics 
and were designed to allow determination of the 
relative risks of ischemia versus bleeding in indi-
vidual patients. Limitations included the omis-
sion of some variables that are known to predict 
the risk of ischemia and bleeding, the failure to 
directly consider the predictors of mortality, and 
the absence of external validation from a con-
temporary data set (as yet). Nonetheless, this 
analysis represents a useful development toward 
individualizing patient care.
Are There Flaws in Trial Design or Conduct?
A highly significant result for the primary out-
come goes a long way toward substantiating the 
view that findings cannot be attributed to chance. 
Figure 3. Balancing Efficacy and Safety Outcomes in SPRINT.
In the SPRINT trial, among 9361 selected patients with a systolic blood pressure of 130 mm Hg or more who were 
randomly assigned to intensive treatment (a systolic blood-pressure target of <120 mm Hg) or standard treatment 
(a target of <140 mm Hg), intensive treatment resulted in a substantially lower rate of the composite primary out-
come of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or cardiovascular death than 
standard treatment and in lower rates of all-cause death and heart failure. However, intensive treatment was asso-
ciated with significantly higher rates of serious adverse events related to hypotension, syncope, and acute kidney 
 injury. Data are from the SPRINT Research Group.31
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Nonetheless, biases in the design and conduct of 
the trial must be ruled out before a genuine 
benefit can be acknowledged.
For instance, the first randomized trial of 
renal denervation in treatment-resistant hyper-
tension, SYMPLICITY HTN-2,37 showed that at 
6 months, systolic blood pressure was markedly 
lower in the treatment group than in the control 
group (mean difference, 31 mm Hg; P<0.0001). 
However, the absence of blinding introduced 
major issues38 (e.g., placebo and Hawthorne ef-
fects, ascertainment bias, and regression to the 
mean). In the subsequent, sham-controlled trial, 
SYMPLICITY HTN-3,39 renal denervation appeared 
to be ineffective, thereby emphasizing the poten-
tial unreliability of unblinded trials.
Limitations in the completeness and quality 
of the data can also corrupt the validity of a 
trial. Not all patients fully comply with intended 
treatment regimens, and some withdraw from 
follow-up. Judgment is required in determining 
whether the extent of nonadherence or with-
drawals casts doubt on the legitimacy of a trial. 
For instance, the ATLAS ACS 2–TIMI 51 trial40 of 
rivaroxaban versus placebo in patients with acute 
coronary syndromes showed highly significant 
between-group differences in favor of the lower 
dose of rivaroxaban with respect to both the 
primary outcome (cardiovascular death, myocar-
dial infarction, or stroke) and cardiovascular 
death alone. But 27.6% of the patients discontin-
ued treatment prematurely, and data on vital 
status were missing for 7.2% of the patients — 
factors that introduced uncertainty. These prob-
lems appeared to be greater in this trial than in 
other large trials that address acute coronary 
syndromes and contributed to the FDA decision 
to withhold its approval of rivaroxaban for this 
indication.41
Do the Findings Apply to My Patients?
The findings of any trial apply to the specific 
patients enrolled and the therapies administered 
(both background and experimental). The ques-
tion of whether the results can be generalized to 
other patients must be considered. For instance, 
the SPRINT trial31 excluded patients younger 
than 50 years of age and those with diabetes or 
a history of stroke. The trial results (Fig. 3) thus 
apply to only approximately 20% of all patients 
with hypertension who are seen in practice.42 
Investigators in the ACCORD trial43 previously 
considered the use of intensive blood-pressure 
control exclusively in patients with type 2 diabetes 
and reported no effect on cardiovascular events 
as compared with standard therapy. Whether the 
divergent results of the SPRINT and ACCORD 
trials are due to differences in patient character-
istics, medications, trial methods, or other factors 
remains undetermined.
The geographic representation in a trial may 
also affect the generalizability of its results. 
Many major trials are multinational, which is an 
advantage in conferring global meaning. But 
health care practices may vary across regions 
(e.g., the use of primary PCI vs. fibrinolysis in 
patients with STEMI). If patient recruitment is 
dominated by one region, worldwide applicabil-
ity may be limited. In addition, genetic, anatomi-
cal, environmental, and dietary differences among 
peoples sometimes make outcomes difficult to 
generalize across countries.
Similarly, the results from single-center trials 
must be viewed with caution. Center-specific ef-
fects, such as particular systems of care and the 
background therapies used, may preclude the gen-
eralizability of the findings, and single-center 
trials often lack quality-control measures. Results 
from single-center studies, even those with a 
reasonable sample size, should rarely serve as 
the basis for changing guidelines unless the re-
sults have been validated in subsequent multi-
center trials. For example, the single-center 
TAPAS trial44 of thrombus aspiration during 
primary PCI, which involved 1071 patients with 
STEMI, showed dramatically lower mortality at 
1 year after PCI and thrombus aspiration than 
after conventional PCI (hazard ratio, 0.60; 95% 
CI, 0.36 to 0.98; P = 0.04). In hindsight, this out-
come was unrealistic given the modest benefit in 
reperfusion success, which was the primary out-
come. However, this study led to widespread 
adoption of thrombus aspiration for many years. 
Two multicenter trials involving more than 
17,000 patients have now convincingly shown that 
routine thrombus aspiration offers no advan-
tages with regard to mortality or cardiovascular 
events.45,46
Finally, by the time the long-term findings 
for the primary outcome of a randomized trial 
become available, advances in care may have 
lessened their relevance to contemporary practice. 
For example, in the SYNTAX and FREEDOM 
trials,47,48 patients with left main or multivessel 
disease were assigned to PCI with first-genera-
tion drug-eluting stents or to CABG. However, 
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contemporary drug-eluting stents represent a 
substantial improvement from first-generation 
devices,49,50 a fact that diminishes the applicabil-
ity of these trials to current practice.
Discussion
A significance level of 5% for the primary effi-
cacy outcome is the minimum requirement if a 
trial is to be declared “positive,” and this level of 
significance should prompt deeper inspection 
into study processes and outcomes. Determining 
whether the evidence justifies the announcement 
of a major advance in medical care or a more 
cautionary note that further studies are warrant-
ed requires a comprehensive approach to all avail-
able evidence by various stakeholders (Fig. 4).
If the efficacy and safety outcomes of the 
trial are convincingly met, the next step is to 
evaluate its overall quality and internal validity. 
It must also be determined whether the findings 
translate into treatment effectiveness (and net 
clinical benefit) in real-world patients. However, 
caution is required when data from nonrandom-
ized registries are used to confirm or refute trial 
findings, given the potential for selection bias 
and residual confounding when such registries 
are used. At the same time, gauging the cost-
effectiveness of treatments across different types 
of health care systems will determine the level of 
reimbursement (which in turn will affect the 
adoption of a new therapy).
For a new drug, the question of whether the 
results of a pivotal trial will satisfy the require-
ments for approval established by regulators 
(e.g., FDA and the European Medicines Agency) 
depends on the totality of the evidence from the 
trial and from all previous, related studies. Often, 
further evidence is required to clarify the safety 
profile of a new drug, and approval may depend 
on the sponsor’s willingness to undertake addi-
tional safety studies (by means of randomized 
trials or observational registries).
Societal guideline committees play an impor-
tant role in synthesizing the knowledge base and 
classifying the strength of evidence for new treat-
ments; their endorsements strongly affect prac-
tice. Ultimately, however, physicians at the point 
of care bear the final responsibility for accurately 
interpreting clinical trial results and for integrat-
ing regulatory and guideline recommendations 
in order to make the best treatment decisions for 
each patient in their care.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank Tim Collier for his help in producing earlier ver-
sions of some of the figures.
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